According to analysts at Future Market Insights (FMI), the global analgesics market is likely to be worth $79 billion by the end of 2028, indicating a compound annual growth rate of 5% over the next 10 years.
Abuse-deterrent opioids are speculated to be a significant growth market following the ongoing opioid addiction crisis in North America, as well as non-opiod painkillers to complement governmental policies that disincentivize opioid prescription. In developing markets, opioids are expected to remain a valuable investment due to the relative scarcity of analgesics generally.
Additionally, FMI reports that leading analgesics manufacturers are developing non-opioid painkillers with innovative extended release formulations, enhancing the ability for cutting-edge analgesics to treat chronic pain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze